InVentiv Health to buy SDI audits from IMS

Share this article:

Privately held inVentiv Health will acquire two of SDI Health's audit businesses worth under $15 million, according to company statements. IMS Health agreed to divest the units when regulators approved its purchase of SDI last year.


The promotional and medical audit businesses will be incorporated into the offerings of inVentiv Health's Campbell Alliance biopharma management consulting unit.


"This is an important step in boosting inVentiv's capabilities in market research and analytics," said Paul Meister, CEO, inVentiv Health, in a statement.


Campbell Alliance already has a market research and analytics group offering a range of longitudinal de-identified patient and prescription data and analytics services. The firm will combine the acquired business with the group, which also provides custom quantitative research, qualitative market research, and key opinion leader identification and mapping.


The deal follows IMS Health's acquisition of SDI Health, formally approved October 31, after which its parent company, Healthcare Technology Holdings, moved forward to divest the two SDI product lines, as per a settlement order proposed by the Federal Trade Commission to preserve competition.


In the settlement order, the FTC had required IMS to sell the two businesses to a buyer within three months of the completion of the deal, or Jan. 31, 2012.


Financial terms were not disclosed, but in a statement about yesterday's sale to inVentiv, IMS revealed that, under the two businesses it divested are a number of different data products, 11 to be exact. These products, which needed to be sold off to satisfy the FTC requirements, represent less than $15 million, or about 10% of SDI's 2011 revenue.

IMS will continue to market its existing medical and promotional services worldwide, the firm said, including the company's National Disease and Therapeutic Index (NDTI) and Integrated Promotional Services (IPS) offerings in the US.

"With the acquisition of SDI, IMS continues to build more innovative and comprehensive capabilities in the patient and payer spaces, consistent with the company's strategy to significantly expand its business in healthcare information, technology and services," IMS concluded.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...